Miyamoto Tomoyuki, Miyamoto Masayuki, Suzuki Keisuke, Ikematsu Akiko, Usui Yasuhiro, Inoue Yuichi, Hirata Koichi
Department of Neurology, Center of Sleep Medicine, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
Sleep Med. 2009 May;10(5):577-80. doi: 10.1016/j.sleep.2008.04.013. Epub 2008 Aug 26.
We investigated cardiac (123)I-metaiodobenzylguanidine (MIBG) scintigraphic assessment as a supportive diagnostic indicator for idiopathic REM sleep behavior disorder (RBD) complicated by moderate to severe obstructive sleep apnea (OSA).
(123)I-MIBG was intravenously injected in 23 idiopathic RBD patients with AHI < 5/h, 9 idiopathic RBD patients with 5 <or= AHI < 15/h, 15 idiopathic RBD patients complicated with moderate to severe OSA with AHI >or= 15/h, and 16 moderate to severe obstructive sleep apnea syndrome (OSAS) patients without RBD by polysomnography.
Cardiac MIBG uptake based on H/M was significantly decreased in RBD patients with or without OSA compared with patients with moderate to severe OSAS without RBD. ROC analysis revealed that a delayed H/M cut-off value of 1.97 was useful for differentiating idiopathic RBD complicated by moderate to severe OSA from moderate to severe OSAS without RBD.
(123)I-MIBG cardiac scintigraphy has the potential to distinguish true RBD from pseudo-RBD associated with OSA. These results are noteworthy because treatment options and follow-up protocols are determined based on evaluation of moderate to severe OSA complicated with RBD, such as overlapping primary sleep disorders.
我们研究了心脏(123)I-间碘苄胍(MIBG)闪烁扫描评估作为特发性快速眼动睡眠行为障碍(RBD)合并中度至重度阻塞性睡眠呼吸暂停(OSA)的辅助诊断指标。
通过多导睡眠图对23例呼吸暂停低通气指数(AHI)<5/h的特发性RBD患者、9例5≤AHI<15/h的特发性RBD患者、15例合并中度至重度OSA且AHI≥15/h的特发性RBD患者以及16例无RBD的中度至重度阻塞性睡眠呼吸暂停综合征(OSAS)患者静脉注射(123)I-MIBG。
与无RBD的中度至重度OSAS患者相比,无论是否合并OSA的RBD患者基于H/M的心脏MIBG摄取均显著降低。ROC分析显示,H/M截止值为1.97时,有助于鉴别合并中度至重度OSA的特发性RBD与无RBD的中度至重度OSAS。
(123)I-MIBG心脏闪烁扫描有潜力区分真正的RBD与与OSA相关的假性RBD。这些结果值得关注,因为治疗方案和随访方案是基于对合并RBD的中度至重度OSA(如重叠的原发性睡眠障碍)的评估来确定的。